The Global Health Body Raises Concern Over Critical Shortage of Obesity Injections
Less than a tenth of patients who could benefit from obesity jabs like Wegovy have access to them, states the global health agency as it releases its first guidance on the therapies.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging more widespread and fairer access to this class of drugs.
Based on forecasts, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be managed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key hurdles to universal availability to the injections that can help people shift substantial body mass, explains the organization.
GLP-1 Therapy Shortage
Despite the current best projected case, the manufacturing of these medications would only suffice for around 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice urges governments and firms to widen availability, through measures like patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and boost satiety so users eat less.
Patients usually see weight reduction in the initial weeks of starting on the weekly injections.
Research indicates users may regain a significant portion after a year of discontinuing the medication, because their typical hunger return.
To be overweight or obese increases your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
